Active substanceInosineInosine
Similar drugsTo uncover
  • Inosie-F®
    solution in / in 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Inosine
    solution in / in 
    Ama Pharm, OOO     China
  • Inozin-Eskom
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Riboxin
    solution in / in 
    ATOLL, LLC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    MAKSFARM, OJSC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    BINNOFARM, CJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    OZONE, LLC     Russia
  • Riboxin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Riboxin
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Riboxin
    solution in / in 
    VEROPHARM SA     Russia
  • Riboxin
    pills inwards 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    ELLARA, LTD.     Russia
  • Riboxin
    solution in / in 
    GROTEKS, LLC     Russia
  • Riboxin
    solution in / in 
    VELFARM, LLC     Republic of San Marino
  • Riboxin of Avexime
    pills inwards 
  • Riboxin Beefus
    solution in / in 
    UPDATE OF PFC, CJSC     Russia
  • Riboxin-Vial
    solution in / in 
    VIAL, LLC     Russia
  • Riboxin-LexT
    pills inwards 
  • Riboxin-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • ASFARMA, LLC     Russia
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    In 1 ml of solution contains:

    active substance: inosine (riboxin) 20 mg;

    Excipients: methenamine (hexamethylenetetramine), sodium hydroxide solution (sodium hydroxide) 1 M, water for injection.

    Description:

    Transparent, colorless or slightly colored liquid.

    Pharmacotherapeutic group:metabolic
    ATX: & nbsp

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Riboxin refers to anabolic nonsteroidal substances that stimulate metabolic processes. Purine derivative, precursor of adenosine triphosphate (ATP); has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, provides pharmacological protection of the kidneys subjected to ischemia during the operation. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle.

    Pharmacokinetics:

    Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In an insignificant amount excreted in the urine.

    Indications:

    Complex therapy of coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides after myocardial infarction, against the background of myocardial dystrophy after the infectious diseases.

    Diseases of the liver (hepatitis, cirrhosis, fatty degeneration).

    Operations on an isolated kidney (as a means of pharmacological protection when turning off blood circulation).
    Contraindications:

    Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age under 18 years (efficacy and safety not established).

    Carefully:Renal failure.
    Dosing and Administration:

    Enter intravenously struino (slowly) or drip (40-60 drops per minute). Treatment begins with the introduction of 200 mg (10 ml of 2% solution) once a day, then, with good tolerability, the dose is increased to 400 mg (20 ml of 2% solution) 1-2 times a day. Duration of treatment is 10-15 days.

    With acute violations of the rhythm of the heart, jet injection in a single dose of 200-400 mg (10-20 ml of a 2% solution) is possible.

    For pharmacological protection of the kidneys subjected to ischemia, riboksin is injected intravenously in a single dose of 1.2 g (60 ml of 2% solution) for 5-15 minutes before clamping the renal artery, and then another 0.8 g (40 ml of 2% solution) immediately after the restoration of blood circulation.

    For intravenous drip of 2% solution, the drug is diluted in 5% glucose solution or isotonic sodium chloride solution (up to 250 ml).

    Side effects:

    Allergic reactions (urticaria, skin itching, skin hyperemia (the drug is canceled).

    Rarely is an increase in the concentration of uric acid in the blood.

    Perhaps an exacerbation of gout (with prolonged use).

    Form release / dosage:Solution for intravenous administration, 20 mg / ml.
    Packaging:

    In ampoules of 5 or 10 ml of neutral glass.

    10 ampoules together with a vial for opening ampoules or a scarifier and instructions for use in a cardboard box.

    When using ampoules with notches, rings and dots, the scarifier or knife is not ampouled.

    Storage conditions:

    In the dark place at a temperature of 15 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:P N000802 / 01
    Date of registration:29.05.2007
    The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspDALHIMFARM, OJSCDALHIMFARM, OJSC
    Information update date: & nbsp23.10.2015
    Illustrated instructions
      Instructions
      Up